Focus on India, emerging markets could drive Dr Reddy's rerating

Dr Reddy’s has gained about 10 per cent from February lows on expectations that some recovery in the US market and its emerging markets (EMs) focus should improve its growth trajectory. The company’s performance during the December quarter showed some green shoots, with a 4 per cent sequential growth in the US.  Analysts believe its US generics business might be finally turning the corner. A few approvals for launches and positive developments on opioid drug Suboxone litigation also bode well, while some relief on regulatory front provides more confidence. The clea.....
Key stories on are available to premium subscribers only.

Already a premium subscriber?

Subscribe to get an across device (Website, Mobile Web, Iphone, Ipad, and Android Phone applications) access to Premium content, Breaking News alerts, Industry Newsletters, Stock and Corporate news alerts, access to Archives and a lot more.